CD274 and lung carcinoma: In addition, subgroup analyses according to TNM stage showed that increased PD-L1 expression impacted OS negatively for lung cancer patients in stage I-III (HR = 1.61, 95% CI: 1.24–2.09, P < 0.001), but not in stage IV (HR = 0.66, 95% CI: 0.33–1.33, P = 0.25).